Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
PHAT compared with NAMS: revenue, margins and what each company keeps, and the suppliers and customers both name
PHAT
Phathom Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
NAMS
NewAmsterdam Pharma Co N.V.
Change
Mkt cap
Revenue
Revenue
vs
Compare
PHAT
Phathom Pharmaceuticals, Inc.
vs
NAMS
NewAmsterdam Pharma Co N.V.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
PHAT: latest quarter is a loss; flow not drawable. NAMS: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only PHAT
2
—
Takeda Pharmaceutical
unlisted
supplier
—
Sandoz
unlisted
supplier
Shared
0
No disclosed counterparties: NAMS.
Only NAMS
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
PHAT, solid
NAMS, dashed
PHAT
Phathom Pharmaceuticals, Inc.
Change
5.73
▼
−7.88%
· post 5.85
Mkt cap
$466.6M
Revenue
$85M
Q3 FY26
Revenue
$175M
FY25
NAMS
NewAmsterdam Pharma Co N.V.
Change
20.05
▼
−3.42%
· post 20.05
Closed
Oct 30 '26
Mkt cap
$2.4B
Revenue
$4M
Q2 FY26
Revenue
$23M
FY25
vs
Compare
Closed
Oct 30 '26
PHAT
Phathom Pharmaceuticals, Inc.
vs
NAMS
NewAmsterdam Pharma Co N.V.
5.73
▼
−7.88%
post 5.85
Price
20.05
▼
−3.42%
post 20.05
$466.6M
Mkt cap
$2.4B
Q3 FY26
$85M
Revenue
$4M
Q2 FY26
FY25
$175M
Revenue
$23M
FY25
Change
Change
PHAT
5.73
▼
−7.88%
vs
NAMS
20.05
▼
−3.42%
Closed
Oct 30 '26